Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...

Whether you're managing Type 1 or Type 2 diabetes, Canadian Insulin offers a wide selection of brand-name insulin products like Lantus, Humalog, and Novolog, all sourced from licensed Canadian ...

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

Nalgonda: A severe shortage of medicines, including life-saving drugs, at Wellness Centres in Nalgonda and Khammam districts ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

Tsimikas, vice president of San Diego’s Scripps Whittier Diabetes Institute, helped deliver positive news for the estimated 7 million Americans who take ...

In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) ...

CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...

Learn about cost, dosage, and more for NovoLog (insulin aspart), a prescription drug that helps manage blood sugar levels in adults and children with diabetes.

Metformin, the sulphonylureas and the TZDs were the most prescribed classes of non-insulin antidiabetic medications, accounting for 96% of all prescriptions in the US.

Medicare covers many insulin pumps. Your coverage will depend on the type of pump you use. We explain Medicare coverage, costs, eligibility, and more.